Advertisement

Medical Management of Co-Morbid Anxiety and Substance Use Disorder

  • E. Jane Marshall
Part of the Series in Anxiety and Related Disorders book series (SARD)

Keywords

Anxiety Disorder Cognitive Behavioral Therapy Social Anxiety Generalize Anxiety Disorder American Psychiatric Association 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amering, M., Bankier, B., Berger P., Griengl, H., Windhaber, J., & Katschnig, H. (1999). Panic disorder and cigarette smoking behaviour. Comprehensive Psychiatry, 40, 35–38.PubMedCrossRefGoogle Scholar
  2. American Psychiatric Association. (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry, 161(Suppl. 11), 1–31.Google Scholar
  3. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Association.Google Scholar
  4. American Psychiatric Association. (1998). Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry, 155(Suppl. 5), 1–34.Google Scholar
  5. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders. Third Edition Revised. Washington, DC: American Psychiatric Association.Google Scholar
  6. American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: American Psychiatric Association.Google Scholar
  7. Babor, T. G., & Del Boca, F. K. (Eds.). (2003). Treatment matching in alcoholism [International Research Monographs in the Addictions (IRMA)]. Cambridge, UK: Cambridge University Press.Google Scholar
  8. Bakker, A., Van Balkom, A. J., & Spinhoven, P. (2002). SSRIs vs. TCAs in the treatment of panic disorder: A meta-analysis. Acta Psychiatrica Scandinavia, 106, 163–167.CrossRefGoogle Scholar
  9. Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 19, 567–596.PubMedCrossRefGoogle Scholar
  10. Ballenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D. J., Borkovec, T. D., Rickels, K., et al. (2001). Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry, 11, 53–58.Google Scholar
  11. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571.PubMedGoogle Scholar
  12. Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology, 56, 893–897.PubMedCrossRefGoogle Scholar
  13. Beresford, T. P., Arciniegas, D., Clapp, L., Martin, B., & Alfers, J. (2005). Reduction of affective lability and alcohol us following traumatic brain injury: A clinical pilot study of anti-convulsant medications. Brain Injury, 19, 309–313.PubMedCrossRefGoogle Scholar
  14. Brady, K. T., Sonne, S. C., & Roberts, J. M. (1995). Sertraline treatment of co-morbid posttraumatic stress disorder and alcohol dependence. Journal of Clinical Psychiatry, 56, 502–505.PubMedGoogle Scholar
  15. Brown, S. A., Irwin, M., & Schuckit, M. A. (1991). Changes in anxiety among abstinent male alcoholics. Journal of Studies on Alcohol, 52, 55–61.PubMedGoogle Scholar
  16. Campbell-Sills, L., & Stein M. B. (2006). Guideline watch: Practice guidelines for the treatment of patients with panic disorder. Arlington, VA: American Psychiatric Association.Google Scholar
  17. Ciraulo, D. A., & Nace, E. P. (2000). Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. American Journal of the Addictions, 9, 276–279.CrossRefGoogle Scholar
  18. Ciraulo, D., Sands, B., & Shader, R. (1988). Critical review of liability for benzodiazepine abuse among alcoholics. American Journal of Psychiatry, 145, 1501–1506.PubMedGoogle Scholar
  19. Ciraulo, D. A., Barnhill, J. G., Greenblatt, D. J., Shader R. I., Ciraulo, A. M., Tarmey, M. F., et al. (1988). Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. Journal of Clinical Psychiatry, 49, 333–337.PubMedGoogle Scholar
  20. Ciraulo, D. A., Sarid-Segal, O., Knapp, C., Ciraulo, A. M., Greenblatt, D. J., & Shader, R. I. (1996). Liability to alprazolam abuse in daughters of alcoholics. American Journal of Psychiatry, 153, 956–958.PubMedGoogle Scholar
  21. Ciraulo, D. A., Barnhill, J. G., Ciraulo, A. M., Sarid-Segal, O., Knapp, C., Greenblatt, D. J., et al. (1997). Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: Subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. Clinical Pharmacology, 37, 64–73.CrossRefGoogle Scholar
  22. Cornelius, J. R., Rukstein, O., Salloum, I., & Clark, D. (2003). Alcohol and psychiatric co-morbidity. Recent Developments in Alcoholism, 16, 375–390.Google Scholar
  23. Dannon, P. N., Iancu, I., Cohen, A., Lowengrub, K., Grunhaus, L., & Kotler, M. (2004). Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry, 4, 16.PubMedCrossRefGoogle Scholar
  24. Dawes, M., & Johnson, B. A. (2004). Pharmacotherapeutic trials in adolescent alcohol use disorders: Opportunities and challenges. Alcohol and Alcoholism, 39, 166–177.PubMedCrossRefGoogle Scholar
  25. De Bie, J., Robaeys, G., & Buntinx, F. (2005). Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice. Acta Gastroenterology Belgium, 68, 68–80. Google Scholar
  26. Edwards, G., Marshall, E. J., & Cook, C. C. H. (2003). The treatment of drinking problems (4th ed.). Cambridge, UK: Cambridge University Press.Google Scholar
  27. Fawcett, J. (1992). Suicide risk factors in depressive disorders and in panic disorder. Journal of Clinical Psychiatry, 53(Suppl.), 9–13.PubMedGoogle Scholar
  28. Fawcett, J., Kravitz, H., McGuire, M., Easton, M., Ross, J., Pisani, V., et al. (2000). Pharmacological treatment for alcoholism: Revisiting lithium and considering buspirone. Alcoholism: Clinical and Experimental Research, 24, 666–674.CrossRefGoogle Scholar
  29. George, D. T., Rawlings, R., Eckardt, M. J., Phillips, M. J., Shoaf, S. E., & Linnoila, M. (1999). Buspirone treatment of alcoholism: Age of onset and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcoholism: Clinical and Experimental Research, 23, 272–278.Google Scholar
  30. Golden, J., O’Dwyer, A. M., & Conroy, R. M. (2005). Depression and anxiety in patients with hepatitis C: Prevalence, detection rates, and risk factors. General Hospital Psychiatry, 27, 431–438.PubMedCrossRefGoogle Scholar
  31. Gossop, M. (2003). Drug addiction and its treatment. Oxford, UK: Oxford University Press.Google Scholar
  32. Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.PubMedGoogle Scholar
  33. Haddad, P. M. (2001). Antidepressant discontinuation syndromes. Drug Safety, 24, 183–197.PubMedCrossRefGoogle Scholar
  34. Hersh, D., & Modesto-Lowe, V. (1998). Drug abuse and mood disorders. In H. Kranzler & B. Rounsaville (Eds.), Dual diagnosis and treatment. New York: Marcel Dekker.Google Scholar
  35. Katz, I. R., Reynolds, C. F., III, Alexopoulos, G. S., & Hackett, D. (2002). Venlafaxine ER as a treatment for generalised anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. Journal of the American Geriatric Society, 50, 18–25.CrossRefGoogle Scholar
  36. Kleber, H., Weissman, M., Rounsaville, B., Wilber, C., Prusoff, B., & Riordan, C. (1983). Imipramine as treatment for depression in addicts. Archives of General Psychiatry, 40, 649–653.PubMedGoogle Scholar
  37. Kranzler, H. (2000). Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol and Alcoholism, 35, 537–547.PubMedCrossRefGoogle Scholar
  38. Kranzler, H., Burleson, J., Del Boca, F., Babor, T., Korner, P., Brown, J., et al. (1994). Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Archives of General Psychiatry, 51, 720–731.PubMedGoogle Scholar
  39. Kushner, M. G., Sher, K. J., & Erikson, D. J. (1999). Prospective analysis of the relation between DSM-III anxiety disorders and alcohol use disorders. American Journal of Psychiatry, 156, 723–732.PubMedGoogle Scholar
  40. Labbate, L. A., Sonne, S. C., Randall, C. L., Anton, R. F., & Brady, K. T. (2004). Does co-morbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Comprehensive Psychiatry, 45, 304–310.PubMedCrossRefGoogle Scholar
  41. Lenze, E. J., Mulsant, B. H., Shear, M. K., Dew, M. A., Miller, M. D., Pollock, B. G., et al. (2005). Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: Results from an 8-week randomized placebo-controlled trial. American Journal of Psychiatry, 162, 146–150.PubMedCrossRefGoogle Scholar
  42. Lingford-Hughes, A., Welch, S., & Nutt, D. (2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction, and co-morbidity: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 18, 293–335.PubMedCrossRefGoogle Scholar
  43. Litten, R. Z., & Allen, J. P. (1999). Medications for alcohol, illicit drug, and tobacco dependence: An update of research findings. Journal of Substance Abuse Treatment, 16, 105–112.Google Scholar
  44. Malcolm, R., Anton, R., Randall, C., Johnston, A., Brady, K., & Thevos, A. (1992). A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism: Clinical and Experimental Research, 16, 1007–1013.CrossRefGoogle Scholar
  45. Malec, E., Malec, T., Gagne, M., & Dongier, M. (1996). Buspirone in the treatment of alcohol dependence: A placebo-controlled trial. Alcoholism: Clinical and Experimental Research, 20, 307–312.CrossRefGoogle Scholar
  46. Mayo-Smith, M. (1997). Pharmacological management of alcohol withdrawal. Journal of the American Medical Association, 278, 144–151.PubMedCrossRefGoogle Scholar
  47. Muller, T. I., Goldenberg, I. M., Gordon, A. L., Keller, M. B., & Warshaw, M. G. (1996). Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Journal of Clinical Psychiatry, 57, 83–89.Google Scholar
  48. National Institute for Clinical Excellence. (2002). Nicotine replacement therapy [NRT] and bupropion for smoking cessation. Technology Appraisal Guidance No 38, London, UK.Google Scholar
  49. National Institute for Clinical Excellence. (2004). The management of anxiety (panic disorder with or without agoraphobia, and generalised disorder) in adults in primary, secondary and community care. Clinical Practice Guideline No. 22. National Collaborating Centre for Mental Health, London, UK, December.Google Scholar
  50. National Institute for Clinical Excellence. (2005a). Obsessive compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. Second draft for consultation, May.Google Scholar
  51. National Institute for Clinical Excellence. (2005b). Post-traumatic stress disorder: The management of PTSD in adults and children in primary and secondary care. Clinical Practice Guideline number 26. National Collaborating Centre for Mental Health, London, UK, March.Google Scholar
  52. Nunes, E., & Levin, F. (2004). Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. Journal of the American Medical Association, 291, 1887–1896.PubMedCrossRefGoogle Scholar
  53. Nutt, (2005a). Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums, 10, 49–56.Google Scholar
  54. Nutt, D. J. (2005b). Death by tricyclic: The real antidepressant scandal? Journal of Psychopharmacology, 19, 123–124.CrossRefGoogle Scholar
  55. Pettinati, H., Volpicelli, J., Kranzler, H., Luck, G., Rukstanlis, M., & Cnaan A. (2000). Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcoholism: Clinical and Experimental Research, 24, 1041–1049.CrossRefGoogle Scholar
  56. Posternak, M. A., & Mueller, T. I. (2001). Assessing the risks and benefits of benzodiazepines for anxiety disorder in patients with a history of substance abuse or dependence. American Journal of the Addictions, 10, 48–68.CrossRefGoogle Scholar
  57. Randall, C. L., Thomas, S., Thevos, A. K., Sonne, S. C., Thomas, S. E., Willard, S. L., et al. (2001). Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression and Anxiety, 14, 255–262.PubMedCrossRefGoogle Scholar
  58. Rickels, K., Downing, R., Schweizer, E., & Hassman, H. (1993). Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry, 50, 884–95.PubMedGoogle Scholar
  59. Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T. (2000). Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. American Journal of Psychiatry, 157, 968–974.PubMedCrossRefGoogle Scholar
  60. Saitz, R., Mayo-Smith, M. F., Roberts, M. S., Redmond, H. A., Bernard, D. R., & Calkins, D. R. (1994). Individualized treatment for alcohol withdrawal: A randomized double-blind controlled trial. Journal of the American Medical Association, 272, 519–523.PubMedCrossRefGoogle Scholar
  61. Scott, J., Gilvarry, E., & Farrell, M. (1998). Managing anxiety and depression in alcohol and drug dependence. Addictive Behaviours, 23, 919–931.CrossRefGoogle Scholar
  62. Sellers, E. M., Naranjo, C. A., Harrison, M., Devenyi, P., Roach, C., & Sykora, K. (1983). Diazepam loading: Simplified treatment of alcohol withdrawal. Clinical Pharmacology and Therapeutics, 34, 822–826.PubMedCrossRefGoogle Scholar
  63. Sellers, E. M., Ciraulo, D. A., DuPont, R. L. Griffiths, R. R., Kosten, T. R., Romach, M. K., et al. (1993). Alprazolam and benzodiazepine dependence. Journal of Clinical Psychiatry, 54(Suppl.), 64–75.PubMedGoogle Scholar
  64. Shaw, G. K., Majumdar, S. K., Waller, S., MacGarvie J., & Dunn, G. (1987). Tiapride in the long term management of alcoholics of anxious or depressive temperament. British Journal of Psychiatry, 150, 164–168.PubMedCrossRefGoogle Scholar
  65. Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2003). Nicotine replacement therapy for smoking cessation (Cochrane review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd .Google Scholar
  66. Simon, N. M., Emmanuel, N., Ballenger, J., Worthington, J. J., Kinrys, G., Korbly, N. B., et al. (2003). Bupropion sustained release for panic disorder. Psychopharmacology Bulletin, 37, 66–72.PubMedGoogle Scholar
  67. Sternbach, H. (1999). The serotonin syndrome. American Journal of Psychiatry, 148, 703–713.Google Scholar
  68. Synderman, S. H., Rynn, M. A., Bellew, K., & Rickels, K. (2004). Paroxetine in the treatment of generalized anxiety disorder. Expert Opinion in Pharmacotherapy, 5, 1799–806.CrossRefGoogle Scholar
  69. Titievsky, J., Seco, G., Barranco, M., & Kyle, E. (1982). Doxepin as adjunctive therapy for depressed methadone maintenance patients: A double-blind study. Journal of Clinical Psychiatry, 43, 454–456.PubMedGoogle Scholar
  70. Tollefson, G., Montague-Clouse, J., & Tollefson, S. (1992). Treatment of co-morbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). Journal of Clinical Psychopharmacology, 12, 19–26.PubMedCrossRefGoogle Scholar
  71. Woody, G., O’Brien, C., & Rickels, K. (1975). Depression and anxiety in heroin addicts: A placebo-controlled study of doxepin in combination with methadone. American Journal of Psychiatry, 132, 447–450.PubMedGoogle Scholar
  72. Woody, G. E., O’Brien, C. P., McLellan, A. T., Marcovici, M., & Evans, B. D. (1982). The use of antidepressants with methadone in depressed maintenance patients. Annals of the New York Academy of Science, 398, 120–127.CrossRefGoogle Scholar
  73. Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavia, 67, 361–370.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • E. Jane Marshall
    • 1
  1. 1.National Addiction Centre, King’s College London, Box 048, Institute of PsychiatryLondonUK SE5 8AF

Personalised recommendations